These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 16921652)
21. Donepezil for Alzheimer's disease. Benjamin B; Burns A Expert Rev Neurother; 2007 Oct; 7(10):1243-9. PubMed ID: 17939763 [TBL] [Abstract][Full Text] [Related]
22. Quality of life and cholinesterase inhibitors: a qualitative study of patients with Alzheimer's disease and their carers. Smith B; Chur-Hansen A; Neale A; Symon J Australas Psychiatry; 2008 Dec; 16(6):433-7. PubMed ID: 18777227 [TBL] [Abstract][Full Text] [Related]
23. Specific symptomatic changes following donepezil treatment of Alzheimer's disease: a multi-centre, primary care, open-label study. Rockwood K; Black S; Bedard MA; Tran T; Lussier I; Int J Geriatr Psychiatry; 2007 Apr; 22(4):312-9. PubMed ID: 17006874 [TBL] [Abstract][Full Text] [Related]
24. [Dementias: mostly clinico-neuropsychological or mostly psychometric diagnosis?]. Spinnler H Ann Ist Super Sanita; 2005; 41(1):75-80. PubMed ID: 16037654 [TBL] [Abstract][Full Text] [Related]
25. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. Beier MT Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151 [TBL] [Abstract][Full Text] [Related]
26. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials? Cortes F; Portet F; Touchon J; Vellas B J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493 [TBL] [Abstract][Full Text] [Related]
27. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan. Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907 [TBL] [Abstract][Full Text] [Related]
28. Drugs for Alzheimer disease. Can Fam Physician; 2005 Nov; 51(11):1485. PubMed ID: 16353830 [No Abstract] [Full Text] [Related]
32. Alzheimer's disease. Kennedy-Malone LM; Fletcher K Lippincotts Prim Care Pract; 1999; 3(2):163-8. PubMed ID: 10426059 [No Abstract] [Full Text] [Related]
33. [Diagnosis and therapy of Alzheimer's disease: what's important for the family doctor?]. Perneczky R; Kurz A MMW Fortschr Med; 2008 Dec; 150(49-50):42-5; quiz 46. PubMed ID: 19133370 [No Abstract] [Full Text] [Related]
34. [Alzheimer drugs for mild cognitive impairment]. Fellgiebel A Neuropsychiatr; 2007; 21(3):230-3. PubMed ID: 17915184 [TBL] [Abstract][Full Text] [Related]
35. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong. Chu LW; Yik PY; Mok W; Chung CP Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606 [TBL] [Abstract][Full Text] [Related]
36. [Alzheimer's disease: from brain lesions to new drugs]. Forette F; Hauw JJ Bull Acad Natl Med; 2008 Feb; 192(2):363-78; discussion 378-80. PubMed ID: 18819689 [TBL] [Abstract][Full Text] [Related]
37. Alzheimer's disease--towards more patient-centred and meaningful clinical outcomes. Chin JJ Ann Acad Med Singap; 2008 Jul; 37(7):535-7. PubMed ID: 18695763 [No Abstract] [Full Text] [Related]
38. Measuring cognitive change in Alzheimer's disease clinical drug trials. Harrison JE J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492 [TBL] [Abstract][Full Text] [Related]
39. [Consensus 2012--diagnosis and treatment of patients with dementia in Switzerland]. Monsch AU; Büla C; Hermelink M; Kressig RW; Martensson B; Mosimann U; Müri R; Vögeli S; von Gunten A; Praxis (Bern 1994); 2012 Sep; 101(19):1239-49. PubMed ID: 22991148 [No Abstract] [Full Text] [Related]